CMT&Me is an observational, non-interventional study, sponsored by Pharnext, to collect Real-World Evidence (RWE) from people living with CMT. The objective of the study is to better understand the impact of the disease on patients’ daily lives: the burden of CMT, its natural history and treatment, and medical, social and pharmacoeconomic effects.
Webinar Recording: Why CMT Biomarkers Can’t Wait Thank you to everyone who joined HNF’s live...
With gratitude and respect: a note to the CMT community from NMD Pharma Dear members of the CMT...
Muscular Dystrophy Association’s Legacy Awards Honor Innovators in Clinical and Scientific...
Webinar Announcement: Biomarkers Can’t Wait – Accelerating the Path to CMT Treatments Biomarkers...
HNF Partners with MDA for CMT Series The Hereditary Neuropathy Foundation (HNF) was honored to...
Join us Saturday, October 4th from 12pm – 8pm October 4, 2025
The Nerve to Cure
CMT Social + Science Day with Evening Fundraiser Dinner
Big News for the CMT-SORD Community Updates from HNF’s TRIAD Partner, Applied Therapeutics In a...
6,000+ Strong Across 72 Countries — 2025 GRIN is Changing the Game for CMT Research! We’re...
A New CMT Treatment Is One Step Closer Augustine Therapeutics Begins Phase I Trial of AGT‑100216...
Mark your calendars for April 24–26, 2025, because the Nashville CMT Summit is bringing the...
0 Comments